First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

  • B. Palterer Experimental and Clinical Medicine Dept., University of Florence, Florence, Italy.
  • G. Vitiello | gianfranco.vitiello@unifi.it Experimental and Clinical Medicine Dept., University of Florence, Florence, Italy.
  • D. Cammelli Rheumatology Section/Immunoallergology Unit, AOU-Careggi, Florence, Italy.

Abstract

Inflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biographies

B. Palterer, Experimental and Clinical Medicine Dept., University of Florence, Florence
Resident in Allergy and Clinical Immunology
G. Vitiello, Experimental and Clinical Medicine Dept., University of Florence, Florence
Resident in Allergy and Clinical Immunology
D. Cammelli, Rheumatology Section/Immunoallergology Unit, AOU-Careggi, Florence
Head of the Reumatology Section of the Immunoallergology Unit
Published
2017-08-03
Info
Issue
Section
Case Reports
Keywords:
Myelodisplastic syndrome, Myositis specific autoantibodies, Anti-TIF1γ, Dermatomyositis.
Statistics
  • Abstract views: 897

  • PDF: 504
How to Cite
Palterer, B., Vitiello, G., & Cammelli, D. (2017). First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome. Reumatismo, 69(2), 75-77. https://doi.org/10.4081/reumatismo.2017.923